Pfizer and Haemophilia

Pfizer helps to find practical approaches to haemophilia care through partnering with various organisations. Through scientific collaboration and long-term investment in new haemophilia therapies, we aim to advance the treatment and address the unmet needs of people with haemophilia.

Pfizer has partnered with various organisations to help find practical approaches to haemophilia care

  • Pfizer is committed to the improvement of long-term outcomes for people with haemophilia and the support they receive to manage their conditions
  • Through scientific collaboration and long-term investment in new haemophilia therapies, we aim to advance the treatment and address the unmet needs of people with haemophilia

Treatment of haemophilia

Haemophilia is quite rare; about 1 in 10,000 people are born with it1. A primary aim of care in haemophilia is to prevent and treat bleeding with the deficient clotting factor2:

  • On-demand: Treatment given at the time of clinically evident bleeding
  • Prophylaxis: Treatment given in order to prevent anticipated bleeding

Milestones in Pfizer Haemophilia

Pfizer continues to invest in the research and development of haemophilia treatment – the key time points for this are outlined in the figure below.

BeneFIX prescribing information can be found here

ReFacto AF prescribing information can be found here

References:

1. World Federation of Hemophilia. What is Hemophilia? Available at: https://elearning.wfh.org/elearning-centres/introduction-to-hemophilia/#what_is_hemophilia (Accessed January 2020). 

2.WFH GUIDELINES Guidelines for the management of hemophilia. Available at: https://onlinelibrary.wiley.com/doi/epdf/10.1111/j.1365-2516.2012.02909.x (Accessed January 2020). 

3. Funding Universe. Genetics Institute, Inchistory. Available at: http://www.fundinguniverse.com/company-histories/genetics-institute-inc-... (Accessed January 2020).  

4. CenterWatch. BeneFIX(coagulation Factor IX (recombinant)). Available at: https://www.centerwatch.com/directories/1067-fda-approved-drugs/listing/3222-benefix-coagulation-factor-ix-recombinant  (Accessed January 2020)

5. Kelley B et al. An improved manufacturing process for Xyntha/ ReFactoAF. Haemophilia 2010;16(5):717–725.

6. ReFactoAF® moroctocogalfa(recombinant coagulation factor VIII) Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/6558/smpc (Accessed January 2020).

7. BioSpace. Wyeth Receives FDA Approval for New BeneFIX Features That Provide Hemophilia B Patients a Simpler and More Convenient Preparation Process for Recombinant Factor IX, published 26th March 2007. Available at: https://www.biospace.com/article/releases/wyeth-receives-fda-approval-for-new-benefix-features-that-provide-hemophilia-b-patients-a-simpler-and-more-convenient-preparation-process-for-recombin/ (Accessed January 2020).

8. Lambert T et al. Reformulated BeneFIX: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B. Haemophilia 2007;13(3):233–243.

9. European Medicines Agency. Assessment report for ReFacto® AF. 2009. Doc ref: EMEA/55167/2009. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Assessment_R... (Accessed January 2020).

10. BeneFIX® (nonacogalfa) Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/6157 (Accessed January 2020).

11. European Medicines Agency. BeneFIXEPAR –procedural steps taken and scientific information after the authorisation. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Procedural_s... (Accessed January 2020).

12.  Pfizer.co.uk. The Rare Disease Consortium. Available at: https://www.pfizer.com/partnering/areas_of_interest/rare_diseases (Accessed January 2020).

13. Electronic medicines compendium. ReFacto AF Patient Information Leaflet. Available at: https://www.medicines.org.uk/emc/product/7956/pil (Accessed January 2020)                                                               

14. Electronic medicines compendium. BeneFIX Patient Information Leaflet. Available at: https://www.medicines.org.uk/emc/product/6157/pil (Accessed: January 2020)

 

 

PP-BEN-GBR-0308. Date of Preparation:  January 2020.